Results 201 to 210 of about 232,812 (303)

MULTIPLE MYELOMA

Annals of Surgery, 1931
openaire   +3 more sources

The cumulative effect of cytogenetic abnormalities on the outcomes of myeloma patients with del(17p) undergoing AHSCT in EBMT centres between 2016 and 2022

British Journal of Haematology, EarlyView.
Claire Comerford, Patrick J. Hayden, Diderik‐Jan Eikema, Linda Koster, Sandra Sauer, Annoek Broers, Neil Rabin, Jean Noel Bastie, Tobias Gedde‐Dahl, Luisa Giaccone, Deborah Richardson, Kristina Carlson, Britta Besemer, Jean‐Marc Schiano de Colella, Robert Zeiser, Laure Vincent, Thomas Pabst, Anne Cairoli, Christine Schuermans, Monica Poiani, Kavita Raj, Joanna Drozd‐Sokolowska, Laurent Garderet, Inas El Najjar, Meral Beksac, Donal P. McLornan   +25 more
wiley   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Ocular adnexal plasmacytoma presenting as a lesion of the plica semilunaris and caruncle in a 21-year-old male. [PDF]

Am J Ophthalmol Case Rep
Al-Kaylani HM, Torres G, Holman CJ, Binkley E, Greiner MA, Goins KM, Smith MC, Syed NA, Matharu KS.   +8 more
europepmc   +1 more source

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

British Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

Anti-CD38 monoclonal antibodies in multiple myeloma and beyond: immunotherapeutic mechanisms, evidence maturity, and clinical positioning. [PDF]

Front Immunol
Yu L, Li C, Guo D, Cui S.
europepmc   +1 more source

Real‐world outcomes of daratumumab, bortezomib, thalidomide and dexamethasone (Dara‐VTd) induction and lenalidomide maintenance in transplant‐eligible multiple myeloma

British Journal of Haematology, EarlyView.
Edvan Q. Crusoé, Glaciano Ribeiro, João Tadeu D. Souto Filho, Jayr Schmidt Filho, Natalia Schutz, Milton A. F. Aranha, Abel Costa, Abrahao Hallack, Fernando V. Pericole, Juliana S. Lima, Breno Gusmão, Eduardo Flávio O. Ribeiro, Jorge P. Vaz, Rosane Bittencourt, Rafael Cunha, Danielle Ovigli, Luiza Berg, Ederson R. Mattos, Angelo Maiolino, Vania Hungria, on behalf of GBRAM   +20 more
wiley   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma

Haematologica, 2017
Sharmilan Thanendrarajan, Erming Tian, Pingping Qu, Pankaj Mathur, Carolina Schinke, Frits van Rhee, Maurizio Zangari, Leo Rasche, Niels Weinhold, Daisy Alapat, William Bellamy, Cody Ashby, Sandra Mattox, Joshua Epstein, Shmuel Yaccoby, Bart Barlogie, Antje Hoering, Michael Bauer, Brian A. Walker, Faith E. Davies, Gareth J. Morgan   +20 more
doaj   +1 more source

Simvastatin as an immunomodulator and anti-myeloma agent - epidemiological, <i>in vitro</i> and murine model studies. [PDF]

Front Immunol
Lion A, Israel AY, Merzon E, Oster H, Weizman A, Luboshits G, Bogen B, Mittelman M, Firer MA.   +8 more
europepmc   +1 more source